The impact of response on bone-directed therapy in patients with multiple myeloma-Reference-Cited by-同舟云学术

The impact of response on bone-directed therapy in patients with multiple myeloma

Published:2013-10-24 Issue:17 Volume:122 Page:2974-2977
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Larocca Alessandra¹,Child J. Anthony²,Cook Gordon³,Jackson Graham H.⁴,Russell Nigel⁵,Szubert Alexander²,Gregory Walter M.²,Brioli Annamaria⁶⁷,Owen Roger G.³,Drayson Mark T.⁸,Wu Ping⁶,Palumbo Antonio¹,Boccadoro Mario¹,Davies Faith E.⁶,Morgan Gareth J.⁶

Affiliation:

1. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy;

2. Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom;

3. St. James’s Institute of Oncology, St. James’s University Hospital, Leeds, United Kingdom;

4. Haematology Department, Freeman Hospital Trust, Newcastle Upon Tyne, United Kingdom;

5. Centre for Clinical Haematology, Nottingham University Hospital (City Campus), Nottingham, United Kingdom;

6. Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom;

7. Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy; and

8. University of Birmingham, Birmingham, United Kingdom

Abstract

Key Points The use of ZOL is better than CLO in the improvement of SREs and survival in symptomatic myeloma patients at diagnosis. Response category posttransplant may influence the impact of bisphosphonate therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/17/2974/1369622/2974.pdf

Reference19 articles.

1. Multiple myeloma.;Palumbo;N Engl J Med,2011

2. Prevention and treatment of myeloma bone disease.;Terpos;Curr Hematol Malig Rep,2012

3. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.;Bataille;J Clin Oncol,1989

4. Targeting bone in myeloma.;Morgan;Recent Results Cancer Res,2012

5. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.;Kyle;J Clin Oncol,2007

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease;Blood Cancer Journal;2024-04-15

2. Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease;Cancers;2023-11-25

3. Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium;Clinical Lymphoma Myeloma and Leukemia;2022-01

4. Recent therapeutic approaches in myeloma;Bone Cancer;2022

5. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group;The Lancet Oncology;2021-03